Jubilant Pharmova Management

Management criteria checks 1/4

Jubilant Pharmova's CEO is Priyavrat Bhartia, appointed in Jun 2023, has a tenure of less than a year. directly owns 0.88% of the company’s shares, worth ₹940.94M. The average tenure of the management team and the board of directors is 1.3 years and 7 years respectively.

Key information

Priyavrat Bhartia

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.9%
Management average tenure	1.3yrs
Board average tenure	7yrs

Recent management updates

Recent updates

CEO

Priyavrat Bhartia (47 yo)

less than a year

Tenure

Mr. Priyavrat Bhartia, MBA, is the Non-Executive Chairman at Digicontent Limited and has been its Non-Executive Director since August 14, 2017. He has been Non-Executive Director of Hindustan Media Venture...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Arvind Chokhany	Group CFO & Whole-Time Director	less than a year	₹53.43m	no data
Laxshmivarahan Ramasubramani	Group Chief Digital & Information Officer	no data	₹16.53m	no data
Naresh Kapoor	Company Secretary & Compliance Officer	1.8yrs	₹6.86m	no data
Praveen Gupta	Executive VP & Head of Direct Taxation	no data	₹21.06m	no data
K.V.S Kumar	Chief Sustainability Officer	no data	₹16.73m	no data
Priyavrat Bhartia	MD & Director	less than a year	no data	0.88% ₹ 940.9m
Arjun Bhartia	Joint MD & Director	less than a year	no data	no data
Prakash Bisht	Executive VP of Group Accounts	no data	no data	no data
Surajit Pal	Head of Investor Relations	no data	no data	no data
Sanjay Gupta	Executive VP & Head of Legal	9.5yrs	₹3.34m	no data
Shantanu Jha	Group Chief Human Resources Officer	1.3yrs	no data	no data
Rajagopal Sankaraiah	Advisor	4.2yrs	₹67.29m	no data

1.3yrs

Average Tenure

49yo

Average Age

Experienced Management: 530019's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Arvind Chokhany	Group CFO & Whole-Time Director	3.1yrs	₹53.43m	no data
Priyavrat Bhartia	MD & Director	7yrs	no data	0.88% ₹ 940.9m
Arjun Bhartia	Joint MD & Director	7yrs	no data	no data
Jinang Parekh	Whole-Time Director	1.3yrs	no data	no data
Shyam Sunder Bhartia	Chairman	45.9yrs	no data	0.084% ₹ 90.4m
Sushil Roongta	Independent Non-Executive Director	7yrs	₹1.76m	no data
Arun Seth	Independent Non-Executive Director	5.6yrs	₹1.38m	0.0013% ₹ 1.3m
Hari Bhartia	Co-Chairman	40.5yrs	₹119.90m	0.23% ₹ 249.8m
Vivek Mehra	Independent Non-Executive Director	7yrs	₹1.85m	no data
Shirish Belapure	Additional Independent Non-Executive Director	1.2yrs	no data	no data

7.0yrs

Average Tenure

66.5yo

Average Age

Experienced Board: 530019's board of directors are considered experienced (7 years average tenure).

Jubilant Pharmova Management

Management criteria checks 1/4

Key information

Recent management updates

Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023

Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023

Jubilant Pharmova Limited Announces Change in Directorate

Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022

Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022

High number of new directors

Recent updates

Third quarter 2024 earnings released: EPS: ₹4.22 (vs ₹0.98 loss in 3Q 2023)

Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023

Second quarter 2024 earnings released: EPS: ₹3.94 (vs ₹0.34 in 2Q 2023)

Price target decreased by 8.9% to ₹395

Jubilant Pharmova Limited to Report Fiscal Year 2024 Results on May 17, 2024

Jubilant Pharmova Limited, Annual General Meeting, Aug 31, 2023

First quarter 2024 earnings released: EPS: ₹0.40 (vs ₹2.96 in 1Q 2023)

Jubilant Pharmova Limited to Report Fiscal Year 2023 Results on Jul 19, 2023

Jubilant Pharmova Limited Announces Change in Directorate

Full year 2023 earnings released: ₹3.83 loss per share (vs ₹26.01 profit in FY 2022)

Jubilant Pharmova Limited to Report Q4, 2023 Results on May 29, 2023

Now 21% undervalued after recent price drop

Price target decreased by 11% to ₹384

Third quarter 2023 earnings released: ₹0.98 loss per share (vs ₹3.20 profit in 3Q 2022)

Jubilant Pharmova Limited to Report Q3, 2023 Results on Feb 03, 2023

Price target decreased to ₹391

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited to Report Q2, 2023 Results on Oct 21, 2022

Jubilant Pharmova Limited Appoints Jaidev Rajpal as Head of Its Generics Business, Effective October 11, 2022

Price target decreased to ₹434

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before October 24, 2022

Jubilant Pharmova Limited, Annual General Meeting, Sep 26, 2022

Consensus forecasts updated

Upcoming dividend of ₹5.00 per share

First quarter 2023 earnings released: EPS: ₹2.96 (vs ₹10.09 in 1Q 2022)

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited Recommends Final Dividend for the Year Ended March 31, 2022, Payable on or Before October 26, 2022

Jubilant Pharmova Limited to Report Q1, 2023 Results on Aug 02, 2022

High number of new directors

Price target decreased to ₹507

Jubilant Pharmova Limited Approves Executive and Board Changes

Consensus EPS estimates fall by 18%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2022, Payable on or Before September 7, 2022

Now 21% undervalued after recent price drop

Investor sentiment improved over the past week

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to ₹711

Second quarter 2022 earnings released: EPS ₹8.97 (vs ₹14.06 in 2Q 2021)

Price target decreased to ₹802

Price target decreased to ₹869

First quarter 2022 earnings released: EPS ₹10.09 (vs ₹5.53 in 1Q 2021)

Jubilant Pharmova Announces That the US FDA Has Placed Roorkee Facility Under Import Alert

Consensus revenue estimates fall to ₹65.7b

Full year 2021 earnings released: EPS ₹36.05 (vs ₹56.40 in FY 2020)

New 90-day low: ₹752

Price target raised to ₹1,021

Analysts update estimates

President of Manufacturing & Whole-Time Director Anant Pande has left the company

CEO of Life Science Ingredients & Whole-Time Director Rajesh Srivastava has left the company

Jubilant Pharmova Limited Announces Directorate Changes

Third quarter 2021 earnings released: EPS ₹13.75 (vs ₹12.77 in 3Q 2020)

Earnings beat expectations, revenue disappoints

New 90-day high: ₹1,026

Jubilant Life Sciences Limited to Report Q3, 2021 Results on Feb 05, 2021

New 90-day high: ₹978

New 90-day high: ₹866

Market bids up stock over the past week

New 90-day high: ₹820

New 90-day low: ₹683

Revenue and earnings miss expectations

Second quarter 2021 earnings released: EPS ₹14.06

Jubilant Life Sciences Limited to Report Q2, 2021 Results on Nov 04, 2020

Independent Non-Executive Director recently bought ₹1.1m worth of stock

Analysts lower EPS estimates to ₹55.56

Price target raised to ₹725

First quarter earnings released

Full year earnings released - EPS ₹56.39